News | December 03, 2010

First Patients Enrolled in Atrial Fibrillation Trial

December 3, 2010 – The initial patients have been enrolled in a trial for treating atrial fibrillation (AF). The DEEP AF trial will evaluate the safety and efficacy of a dual epicardial/endocardial procedure, or hybrid procedure, using AtriCure’s minimally invasive surgical ablation platform. In addition, it will use Thermocool catheter ablation products from Biosense Webster.

The first procedure was performed in a hybrid room at Sentara Norfolk General Hospital in Norfolk, Va., by Jonathan Philpott, M.D., Ian Woollett, M.D., and John Onufer, M.D. Philpott, Woollett and Onufer are co-principal investigators of the trial and are collaborating with Robert Bernstein, M.D., and Philip Gentlesk, M.D.

The hybrid procedure, designed to treat patients with persistent and long-standing atrial fibrillation, combines the benefits of both minimally invasive surgical ablation and catheter ablation and mapping techniques. The feasibility trial will enroll 30 patients and is being conducted at six U.S. medical centers.

“We believe that this investigational hybrid procedure has the potential to represent an important advancement in the treatment of patients with persistent AF,” Onufer said. “These patients represent the largest segment of the AF population and currently have limited effective treatment alternatives. Our initial experience with this hybrid procedure suggests that it represents a highly promising AF treatment.”

“Our preliminary experience has been that the procedure is both safe and effective,” Philpott said. “The partnership that this hybrid procedure creates between the electrophysiologist and the cardiac surgeon provides patients with a comprehensive ablation and mapping procedure, leveraging the skills and technologies of each specialist.”

To date, the U.S. Food and Drug Administration (FDA) has not cleared any products for treating patients with persistent AF.

For more information:

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Overlay Init